Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Aug 15;17(8):e0273170.
doi: 10.1371/journal.pone.0273170. eCollection 2022.

Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease

Thomas M Siler  1 , Renu Jain  2 , Kathryn Collison  2 , Raj Sharma  3 , Laura Sutton  2 , Jamie Rees  4 , David I Bernstein  5
Affiliations
Clinical Trial

Correct use and ease-of-use of placebo ELLIPTA dry-powder inhaler in adult patients with chronic obstructive pulmonary disease

Thomas M Siler et al. PLoS One. .

Abstract

Background: Inhaler technique errors are common in chronic obstructive pulmonary disease (COPD) treatment, potentially leading to poor disease management. Our pooled analysis approach assessed correct use and ease-of-use of a placebo ELLIPTA dry-powder inhaler (DPI) in patients with COPD.

Methods: Adults with COPD from open-label/non-blinded studies evaluating a placebo ELLIPTA DPI and reporting outcomes of correct use (based on the ELLIPTA DPI patient information leaflet [PIL]) and/or ease-of-use were included. Correct use and ease-of use at study end were primary and secondary endpoints, respectively. Data from patients in the placebo ELLIPTA DPI arm of each study were pooled, and the intent-to-treat (ITT) population was used for all analyses.

Results: Four placebo ELLIPTA DPI studies, reporting correct use (n = 4) and ease-of-use (n = 2), were included in the analysis. The ITT population comprised 1232 patients (mean age 66.2 years). For the primary endpoint, 80.1% (n = 975/1217) of patients demonstrated correct use at study end (95% confidence interval [CI]: 77.8%-82.3%). For the secondary endpoint, 95.7% (n = 797/833) of patients rated placebo ELLIPTA DPI use "easy"/"very easy" at study end (95% CI: 94.1%-97.0%). Correct use and "easy"/"very easy" user ratings remained high across younger (40-64 years) and older (≥65 years) age groups.

Conclusions: Across age groups, most patients used the placebo ELLIPTA DPI correctly and rated it "easy"/"very easy" to use. Consistent with the Global Initiative for Chronic Obstructive Lung Disease 2021 report, our findings emphasize that proper training and clear instructions on PILs are important for optimal inhaler use.

PubMed Disclaimer

Conflict of interest statement

RJ, KC, RS, LS, and JR report employment with, and stock/share ownership in, GSK during study conduct. KC is currently employed by AstraZeneca and LS is no longer employed by GSK. TMS received research support from West-Ward Pharmaceuticals, Theravance Biopharma US, Inc., GSK, Pearl Therapeutics, Chiesi, AstraZeneca, Novartis, Boehringer Ingelheim, Forest, Compleware, Evidera, Oncocyte, Teva, Vapotherm, Sunovion, Proterix BioPharma, Seer, and Sanofi. TMS has also received speaker fees from GSK, Mylan Inc./Theravance Biopharma US, Inc., and Sunovion, and consulting fees from Vapotherm. DIB received grant/research/clinical trial support from GSK, Teva, AstraZeneca, Pearl Therapeutics, Novartis, Genentech, Inc., Merck, Boehringer Ingelheim, Amgen, Aimmune, Shire, and Biocryst and consulted/participated in advisory boards for GSK, ALK America, Gerson-Lehman, and Guidepoint Global. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Database search flow diagram. COPD, chronic obstructive pulmonary disease.
Fig 2
Fig 2. Patient flow, including study completion and withdrawal. ITT, intent-to-treat.
Fig 3
Fig 3. Correct use of the placebo ELLIPTA DPI at study end by age group (n = 1217).
The 95% CI for the percentages is calculated using the exact binomial distribution. DPI, dry-powder inhaler; CI, confidence interval.
Fig 4
Fig 4. Ease-of-use of the placebo ELLIPTA DPI at study end by age group (n = 833).
The 95% CI for the percentages is calculated using the exact binomial distribution. CI, confidence interval; DPI, dry-powder inhaler.
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2022 report). 2022. Available from https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22....
    1. Chrystyn H, van der Palen J, Sharma R, Barnes N, Delafont B, Mahajan A, et al. Device errors in asthma and COPD: systematic literature review and meta-analysis. NPJ Prim Care Respir Med. 2017;27: 22. doi: 10.1038/s41533-017-0016-z - DOI - PMC - PubMed
    1. Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102: 10–19. doi: 10.1016/j.rmed.2007.07.031 - DOI - PubMed
    1. Mehuys E, Boussery K, Adriaens E, Van Bortel L, De Bolle L, Van Tongelen I, et al. COPD management in primary care: an observational, community pharmacy-based study. Ann Pharmacother. 2010;44: 257–266. doi: 10.1345/aph.1M481 - DOI - PubMed
    1. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest. 2000;117: 542–550. doi: 10.1378/chest.117.2.542 - DOI - PubMed

Publication types